A regulatory perspective on the development of gene therapy for Parkinson's disease.
Havert
Michael B
MB
Food and Drug Administration, Center for Biologics Evaluation and Review, Office of Cellular, Tissue, and Gene Therapies, Division of Cellular and Gene Therapies, Rockville, MD 20852, USA. mike.havert@fda.hhs.gov
D015316:Genetic Therapy / Q000331:legislation & jurisprudence*; D005822:Genetic Vectors; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration